Tags

Type your tag names separated by a space and hit enter

[Pharmacogenetics and anti-inflammatory effect of HMG-CoA reductase inhibitors].
Arq Bras Endocrinol Metabol. 2007 Jun; 51(4):520-5.AB

Abstract

Atherosclerosis is a result from the association of lipid deposition in the arterial wall and inflammatory process. This inflammatory process may be detected by clinical markers of systemic inflammation, such as ultrasensible C-reactive protein, which is associated with cardiovascular risk, independently of lipid levels. Statins reduce the inflammation associated to atherosclerosis, which may be verified by a reduction of the C-reactive protein levels. It seems that statins alter immune function by modulating post-translational protein prenylation. Individual genetic variations are associated with modulation of statins lipid-lowering effect; however, few studies have related the effect of the genetic variants with anti-inflammatory effect of statins. In addition to the genes involved in the cholesterol metabolism, genetic factors affecting statins pharmacodynamics and/or pharmacokinetics are potentially responsible for lipid and anti-inflammatory effects.

Authors+Show Affiliations

Laboratório de Fisiopatologia Experimental, Universidade do Extremo Sul Catarinense, Criciúma, SC.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

por

PubMed ID

17684611

Citation

Rosendo, Alexandre B., et al. "[Pharmacogenetics and Anti-inflammatory Effect of HMG-CoA Reductase Inhibitors]." Arquivos Brasileiros De Endocrinologia E Metabologia, vol. 51, no. 4, 2007, pp. 520-5.
Rosendo AB, Dal-Pizzol F, Fiegenbaum M, et al. [Pharmacogenetics and anti-inflammatory effect of HMG-CoA reductase inhibitors]. Arq Bras Endocrinol Metabol. 2007;51(4):520-5.
Rosendo, A. B., Dal-Pizzol, F., Fiegenbaum, M., & Almeida, S. d. (2007). [Pharmacogenetics and anti-inflammatory effect of HMG-CoA reductase inhibitors]. Arquivos Brasileiros De Endocrinologia E Metabologia, 51(4), 520-5.
Rosendo AB, et al. [Pharmacogenetics and Anti-inflammatory Effect of HMG-CoA Reductase Inhibitors]. Arq Bras Endocrinol Metabol. 2007;51(4):520-5. PubMed PMID: 17684611.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pharmacogenetics and anti-inflammatory effect of HMG-CoA reductase inhibitors]. AU - Rosendo,Alexandre B, AU - Dal-Pizzol,Felipe, AU - Fiegenbaum,Marilu, AU - Almeida,Silvana de, PY - 2006/08/25/received PY - 2007/02/26/accepted PY - 2007/8/9/pubmed PY - 2008/8/1/medline PY - 2007/8/9/entrez SP - 520 EP - 5 JF - Arquivos brasileiros de endocrinologia e metabologia JO - Arq Bras Endocrinol Metabol VL - 51 IS - 4 N2 - Atherosclerosis is a result from the association of lipid deposition in the arterial wall and inflammatory process. This inflammatory process may be detected by clinical markers of systemic inflammation, such as ultrasensible C-reactive protein, which is associated with cardiovascular risk, independently of lipid levels. Statins reduce the inflammation associated to atherosclerosis, which may be verified by a reduction of the C-reactive protein levels. It seems that statins alter immune function by modulating post-translational protein prenylation. Individual genetic variations are associated with modulation of statins lipid-lowering effect; however, few studies have related the effect of the genetic variants with anti-inflammatory effect of statins. In addition to the genes involved in the cholesterol metabolism, genetic factors affecting statins pharmacodynamics and/or pharmacokinetics are potentially responsible for lipid and anti-inflammatory effects. SN - 0004-2730 UR - https://www.unboundmedicine.com/medline/citation/17684611/[Pharmacogenetics_and_anti_inflammatory_effect_of_HMG_CoA_reductase_inhibitors]_ L2 - https://medlineplus.gov/cholesterolmedicines.html DB - PRIME DP - Unbound Medicine ER -